Currently out of the existing stock ratings of Chris Pasquale, 36 are a BUY (81.82%), 8 are a HOLD (18.18%).
Analyst Chris Pasquale, currently employed at NEPHRON RESEARCH, has had 62.98% of price targets met with an average potential upside of 28.51%, reached in 209 days on average. Previously, Chris Pasquale worked at JPMORGAN, GUGGENHEIM, MORGAN STANLEY.
Chris Pasquale has documented 86 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on EW, Edwards Lifesciences Corp at 21-Jul-2025.
Analyst best performing recommendations are on PRCT (PROCEPT BIOROBOTICS CORP).
The best stock recommendation documented was for PRCT (PROCEPT BIOROBOTICS CORP) on 10/11/2021. The price target of $45 was fulfilled within 2 days with a profit of $3.45 (8.3%), with a performance score of 41.52.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-May-2026
$93
$9.67 (11.60%)
$82
16 days ago
(30-Oct-2026)
4/5 (80%)
$10.71 (13.01%)
40
Buy Since 07-Oct-2026
$115
$31.67 (38.01%)
$67
1 months 8 days ago
(07-Oct-2026)
10/14 (71.43%)
$30.7 (36.42%)
68
Buy Since 16-Jun-2025
$102
$18.67 (22.40%)
$93
1 months 28 days ago
(18-Sep-2026)
4/8 (50%)
$12.65 (14.16%)
180
Buy Since 21-Jul-2021
$95
$11.67 (14.00%)
$95
1 months 28 days ago
(18-Sep-2026)
9/13 (69.23%)
$5.65 (6.32%)
159
Buy Since 21-Aug-2025
$96
$12.67 (15.20%)
$90
3 months 11 days ago
(04-Aug-2026)
1/3 (33.33%)
$9.06 (10.42%)
278
What Year was the first public recommendation made by Chris Pasquale?
